Close Menu

Aw, A Success

A Forbes article entitled, “Genomics: No Longer A Failure,” says that Human Genome Sciences and Vertex Pharmaceuticals are finally living up to the hype promised during Human Genome Project. Human Genome saw positive results in a second study of its lupus drug, Benlysta, and Vertex presented mid-stage results of its hepatitis C drug, telaprevir, that indicated it could work as well if taken twice a day as three times a day, which is how it is currently being tested.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.